# PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

> **NCT02226965** · PHASE2 · COMPLETED · sponsor: **Sierra Oncology LLC - a GSK company** · enrollment: 45 (actual)

## Conditions studied

- Lymphoma, Diffuse Large B-Cell

## Interventions

- **DRUG:** PNT2258

## Key facts

- **NCT ID:** NCT02226965
- **Lead sponsor:** Sierra Oncology LLC - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-07-11
- **Final completion:** 2018-08-22
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02226965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02226965, "PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02226965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*